A Randomized, Phase 1, Open-Label Study in Healthy HIV-Negative Women to Evaluate the Pharmacokinetics, Safety and Bleeding Patterns Associated with 90-Day Use of Matrix Vaginal Rings Containing 200 mg Dapivirine and 320 mg
Document Type
Data Set
Publication Date
9-27-2024
Abstract
The International Partnership for Microbicides (IPM), which was acquired by the Population Council in 2022, is the developer of the dapivirine vaginal ring and a multipurpose prevention technology (MPT) vaginal ring containing dapivirine and levonorgestrel. Two Phase 1 trials, evaluating pharmacokinetics, safety, bleeding patterns, acceptability, adherence and the vaginal microenvironment of the dapivirine levonorgestrel ring were conducted at sites in the United States by the Microbicide Trials Network (MTN). These data sets support the bleeding and acceptability analyses from one of the clinical trials (MTN-044).
Recommended Citation
Friedland, Barbara and Holly Gundacker. 2024. "A Randomized, Phase 1, Open-Label Study in Healthy HIV-Negative Women to Evaluate the Pharmacokinetics, Safety and Bleeding Patterns Associated with 90-Day Use of Matrix Vaginal Rings Containing 200 mg Dapivirine and 320 mg," Harvard Dataverse, https://doi.org/10.7910/DVN/VZLUFP.
DOI
10.7910/DVN/VZLUFP
Language
English
Project
International Partnership for Microbicides (IPM)
https://doi.org/10.7910/DVN/VZLUFP
